enVVeno Medical NVNO Investor Presentation February 2023

enVVeno Medical (Nasdaq: NVNO) develops surgical and non-surgical replacement venous valve technologies to address chronic venous insufficiency (CVI). The company is advancing its VenoValve® through a U.S. pivotal trial targeting 2.5 million patients, with an upcoming first-in-human study for a non-surgical alternative targeting 3.5 million patients.